Success Story: From Protein Structure Discovery to NIW Approval in Computational Biology
Client’s Testimonial:
"I’m really happy with the service I’ve received. The team was professional, efficient, and always on top of things. Communication was clear, and I felt well-supported throughout the process. I appreciate all the effort and attention to detail that went into everything. Thank you for all your hard work!”
On March 4th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Research Associate in the Field of Computational Biology (Approval Notice).
General Field: Computational Biology
Position at the Time of Case Filing: Postdoctoral Research Associate
Country of Origin: India
State of Residence at the Time of Filing: New Hampshire
Approval Notice Date: March 4th, 2026
Processing Time: 10 months, 3 days (Premium Processing Upgrade Requested)
Case Summary:
Drug discovery often begins with a difficult question: how do scientists identify promising therapeutic targets when the relevant proteins are poorly characterized or not yet well understood? In this NIW case, North America Immigration Law Group (Chen Immigration Law Associates) represented a researcher whose work addresses that challenge through computational biology. Holding a Ph.D. in computational biology and bioinformatics, our client built a strong case around research that uses advanced computational techniques to identify three-dimensional structures and novel inhibitors for therapeutic protein targets, helping expand the possibilities for future treatment development.
Research That Connects Computation and Medicine
Through the application of advanced computational methods to uncover structural information and discover potential inhibitors for difficult protein targets, our client’s research supports the broader effort to improve how new therapies are identified and developed. In preparing the petition, we emphasized that this kind of work has practical value because it helps reduce uncertainty in the early stages of drug discovery and strengthens the scientific basis for therapeutic development.
A recommendation letter captured the strength of her profile clearly, describing her as “a computational biology researcher at the highest echelon of our field.” The letter also emphasized: “She has proven her expertise through her impactful research into machine learning models, their practicality in drug discovery and development processes, and malaria treatment, as well as her breadth of published works too varied to detail here in full, and the considerable importance of her work to medical advancement.”
A Record of Scholarship, Trust, and Growing Impact
Her research has resulted in 7 peer-reviewed journal articles, along with 1 first-authored conference abstract, 1 first-authored preprint, and 2 first-authored book chapters. This pattern of authorship reflected a sustained leading role in developing and communicating research findings.
Her standing in the academic community was further supported by her peer review service. Having completed at least 11 reviews, she demonstrated the type of trusted judgment that journals rely on when selecting experts to evaluate scientific work. In a case like this, peer review service helped show that her expertise had already been recognized by other researchers in the field. Her work had also generated independent reliance. With 66 citations to her publications, her findings were already being used by other scientists in their own studies.
Support for Work with Broader Scientific Value
Another important feature of the case was research funding. Her study had received support from India’s Department of Science and Technology, an additional objective indicator that her work had been recognized as valuable and worthy of investment. When combined with her publication record, citation history, and peer review activity, this funding helped reinforce that she was well-positioned to continue making meaningful contributions in computational biology and therapeutic discovery.
The Result
This NIW approval reflected a clear and well-supported case for the value of computational biology in modern medicine. We are delighted by this approval and look forward to her continued contributions to computational biology, drug discovery, and the development of new therapeutic strategies.